Geetanjali Jindal,

The dose of ASV to be used in a neonatal snake bite has not been documented in literature and remains open to further research. There have been reports of use of high doses of ASV in literature in older age groups(1). Existing guidelines are silent on the dosing schedule of ASV in neonates(2). Taking these facts into consideration, we preferred to continue with ASV dosing beyond 25 vials encouraged by a definite clinical response in the form of improving respiratory and neuromuscular paralysis. The objective of this case report is to share our experience of treating a neonate with snake bite at a tertiary care centre and suggest possibility of further research in this area and not to mislead the peripheral doctors.